Clinical utility of the systemic immune-inflammation index for predicting survival in esophageal squamous cell carcinoma after radical radiotherapy.

Abstract

Aim: To explore the clinical utility of the systemic immune-inflammation index (SII) for predicting the prognosis of esophageal squamous cell carcinoma (ESCC). Patients & methods: After calculating the SII in 180 patients with ESCC, the relationship between SII values and the pre-/post-radiotherapy SII ratio and overall survival was determined. Results: The median overall survival was 649 days for the entire group and 909 and 466 days for the high and low pre-/post-radiotherapy SII ratio groups, respectively. Multivariate analysis identified Karnofsky performance status (p = 0.045), lymphatic metastasis (p = 0.032), mid-radiotherapy SII (p < 0.001) and pre-/post-radiotherapy SII ratio (p = 0.003) as independent prognostic factors. Conclusion: The pre-/post-radiotherapy SII ratio and mid-radiotherapy SII are potentially effective markers for predicting ESCC prognosis.

• Authors: Yuan Wang, Jiahua Lyu, Hongyuan Jia, Long Liang, Ling Xiao, Yudi Liu, Xiao Liu, Ke Li, Taiyu Chen, Rongke Zhang, Hangyue Zhang, Chunhan Tang, Tao Li
• Journal: Future oncology (London, England) (Future Oncol) Vol. 17 Issue 20 Pg. 2647-2657 (Jul 2021) ISSN: 1744-8301 [Electronic] England
• PMID: 34008415 (Publication Type: Journal Article)

Topics

• Adult
• Aged
• Aged, 80 and over
• Blood Platelets (immunology)
• Chemoradiotherapy (methods, statistics & numerical data)
• Clinical Decision-Making
• Esophageal Neoplasms (blood, immunology, mortality, therapy)
• Esophageal Squamous Cell Carcinoma (blood, immunology, mortality, therapy)
• Feasibility Studies
• Female
• Humans
• Inflammation (blood, diagnosis)
• Kaplan-Meier Estimate
• Lymphocyte Count
• Lymphocytes (immunology)
• Male
• Middle Aged
• Neutrophils (immunology)
• Patient Selection
• Platelet Count
• Prognosis
• Risk Assessment (methods, statistics & numerical data)
• Survival Analysis
• Treatment Outcome